Melike Ersöz | Cancer Biology | Best Researcher Award

Published on by Molecular Biologist

Assoc. Prof. Dr. Melike Ersöz | Cancer Biology | Best Researcher Award 

ASSOCIATE PROFESSOR, at Demiroğlu Bilim University, Turkey.

Assoc. Prof. Melike Ersöz is a distinguished molecular biologist and biochemist specializing in nanomedicine, apoptosis, oxidative stress, and cancer research. Currently serving at Demiroğlu Bilim University, Faculty of Arts and Sciences, Department of Molecular Biology and Genetics, she has over two decades of academic and research experience. Her scientific journey spans stem cell differentiation, nanoparticle-based drug delivery, and the biochemical pathways of cancer progression. She earned her reputation as a dedicated researcher through her innovative studies on mesenchymal stem cell differentiation into hepatocytes, toxicity and anti-cancer mechanisms of nanoparticles, and bioactive compounds’ apoptotic effects on cancer cells. With numerous publications in internationally indexed journals, she contributes significantly to molecular oncology and nanotechnology-based therapies. Melike Ersöz is also an active mentor, supervising theses on novel cancer treatments and nanoparticle-mediated therapies. Her outstanding achievements have earned her several honors, including prestigious fellowships and awards for oral presentations at leading scientific congresses. 🌟

Professional Profile

Scopus

🎓 Education

Melike Ersöz holds a PhD in Biochemistry (2014) from Yıldız Technical University, where she researched the optimization of cord-derived mesenchymal stem cells into hepatocytes under the guidance of Prof. Dr. Adil Allahverdiyev. She completed her Master’s in Bioengineering (2007) at the same university, investigating polyacrylic acid toxicity in cancer and fibroblast cells. Additionally, she earned a Bachelor’s degree in Biology from Istanbul University Faculty of Science (2003), solidifying her foundation in molecular and cellular sciences. To further expand her multidisciplinary expertise, she completed a Bachelor’s in Occupational Health and Safety (2022) at the University of Health Sciences and pursued Associate Degrees in Law (Justice Program) at Anadolu University (2020) and Medical Laboratory Techniques at Istanbul University (1997). This diverse academic portfolio enabled her to bridge the gap between molecular research, health sciences, and safety regulations, enriching her approach to biomedical innovations. 🎓📚

💼 Professional Experience

Assoc. Prof. Ersöz began her academic career as a Lecturer in 2008 at Istanbul Bilim University, where she taught medical laboratory sciences and molecular techniques. In 2014, she was promoted to Assistant Professor in the Department of Molecular Biology and Genetics, contributing significantly to molecular cancer research. By 2022, she achieved the Associate Professor title at Demiroğlu Bilim University, demonstrating her academic leadership and research excellence. She also served as Vice Dean of the Faculty of Arts and Sciences and Head of the Medical Laboratory Techniques Program, shaping educational policies and guiding future scientists. She has managed and participated in several TUBITAK-funded projects and higher education-supported research on nanoparticle drug delivery, cancer apoptosis, and oxidative stress mechanisms. As a mentor, she supervised multiple MSc theses on glioma cell therapy and antioxidant studies. Through interdisciplinary collaborations, she has advanced nanotechnology applications in molecular medicine. 🧬🔬

🔍 Research Interests

Melike Ersöz’s research lies at the intersection of molecular oncology, nanomedicine, and biochemical therapeutics. Her primary focus is the cytotoxic, apoptotic, and antioxidant effects of bioactive compounds and nanoparticle-based drug delivery systems on cancer cells, particularly gliomas and breast cancer. She explores how polyphenols (quercetin, sinapic acid, hesperetin) and natural extracts like green tea and Turkish coffee induce apoptosis through pathways such as JNK, p38, and ER stress. Additionally, she investigates epigenetic modulation, gene methylation profiles (e.g., KLF4 in diabetic nephropathy), and heat shock protein expression in cancer models. Her expertise extends to stem cell differentiation into hepatocytes for regenerative medicine applications. By integrating molecular biology, biochemistry, and nanotechnology, she aims to develop targeted, less toxic cancer therapies. Her translational research contributes to precision medicine, improving understanding of oxidative stress, apoptosis signaling, and drug resistance in cancer therapy. 🌱🧪

🏆 Awards & Recognition

Assoc. Prof. Ersöz has received several prestigious awards for her groundbreaking research. In 2018, she was awarded a Scholarship from FEBS (Federation of European Biochemical Societies) in the Czech Republic, recognizing her innovative cancer therapy studies. She earned the Oral Presentation Second Prize at the 38th Turkish Endocrinology and Metabolism Diseases Congress & 2nd National Lipid Symposium (2016) for her outstanding research on metabolic diseases. In 2014, she received full Congress Registration Support for the 22nd International Congress of Clinical Chemistry and Laboratory Medicine (IFCC WorldLab) and the 26th National Congress of the Turkish Biochemical Society, reflecting her contribution to the global biochemical community. Her recognition extends beyond awards—her publications are widely cited, influencing molecular oncology and nanomedicine fields. Through her research leadership, she continues to inspire young scientists and contribute to national and international collaborative projects. 🏅🌍

📚 Top Noted Publications 

Melike Ersöz has authored 25+ high-impact international journal articles focusing on cancer apoptosis, nanotechnology, and antioxidant mechanisms. Her notable works include studies on quercetin-loaded nanoparticles in glioma therapy, sinapic-acid-based nanoformulations, and the methylation profile of KLF4 in diabetic nephropathy. She has explored how polyacrylic acid, boric acid-treated green tea, and Turkish coffee extracts induce apoptosis in glioma and breast cancer models. Her articles appear in prestigious journals such as ACS Omega, Archives of Medical Research, Environmental Toxicology, and Pharmaceutical Development and Technology. Additionally, she contributed to TUBITAK-funded projects on cancer cell oxidative stress and supervised multiple MSc theses on nanoparticle therapeutics. She actively presents her research at international conferences, including the International Congress of Multidisciplinary Studies in Medical Sciences. Her work integrates molecular biology, nanomedicine, and natural bioactive compounds to advance precision oncology. 🔗📖

🔗 Selected Publications with Links & Citations

1️⃣ Occupational Health and Safety in a Hazardous Waste Disposal Facility Using Industry 4.0 Technologies

Demir, Ersöz, Özcan & Demir – Frontiers in Life Sciences and Related Technologies

  • Published: December 30, 2024 (accepted Oct 19, 2024) in Frontiers in Life Sciences and Related Technologies, Volume 5(3) pubs.acs.org+4dergipark.org.tr+4dergipark.org.tr+4

  • DOI: 10.51753/flsrt.1498808

  • Highlights:

    • Applied Fine Kinney risk analysis to assess 68 critical hazards in a hazardous waste plant.

    • Integration of Industry 4.0 tools (e.g., IoT sensors, real-time monitoring, semi-automated robotics) to reduce direct worker exposure.

    • Demonstrated how automation mitigates accident risks and enhances compliance with OHS standards.

2️⃣ Sinapic-Acid-Loaded Nanoparticles: Cytotoxic, Antiapoptotic, Antioxidant Activity

Poyraz, Akbaş, Duranoğlu, Acar, Mansuroğlu & Ersöz – ACS Omega

  • Published: September 17, 2024; ACS Omega 2024, 9, 39, 40329–40345 dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2dergipark.org.tr+2arxiv.orgpubs.acs.org+1pubs.acs.org+1

  • DOI: 10.1021/acsomega.4c00216

  • Key Terms: 170 nm PLGA nanoparticles encapsulating sinapic acid (SaNPs), optimized via experimental design.

  • Core Findings:

    • SaNPs displayed IC₅₀ in MCF‑7 cells at ~180 µg/mL (24 h), ~168 µg/mL (48 h), ~145 µg/mL (72 h).

    • No significant toxicity in healthy MCF‑10A cells at these concentrations.

    • Mechanisms of action: decreased PCNA expression, increased apoptosis (TUNEL), raised MDA levels, decreased SOD activity, increased GSH and catalase, and elevated caspase‑3 activation.

3️⃣ Turkish Coffee Induces Apoptosis in Glioma Cells

  • Journal: Sigma Journal of Engineering and Natural Sciences, 2024

  • Overview: Reported that bioactive compounds in Turkish coffee trigger apoptotic mechanisms in glioma cells. Frequently cited in natural-product apoptosis research, though full bibliographic details are sparse in mainstream indexing sources.

4️⃣ Gallic Acid Effects on Glioma Cells via p38/JNK Pathway

  • Pak. J. Pharm. Sci., 2023

  • Summary: Demonstrated induction of apoptosis in glioma cells through activation of the p38/JNK signaling cascade, making it a referenced mechanism in cancer pathway studies.

5️⃣ Polyacrylic Acid Toxicity in Cancer Cell Lines

  • The EuroBiotech Journal, 2021

  • Focus: Investigated cytotoxic impacts of polyacrylic acid (PAA), commonly used in biomedical applications, on various cancer cell lines. Heavily cited in biomaterial safety/toxicity literature.

6️⃣ Quercetin-Loaded Nanoparticles Enhance Glioma Cytotoxicity

  • Pharmaceutical Development & Technology, 2020

  • Significance: One of the earlier studies showing that quercetin-loaded nanocarriers significantly increase cytotoxicity toward glioma cells—pivotal in establishing nanodelivery strategies for brain tumor therapy.

Conclusion

Assoc. Prof. Melike Ersöz is a highly suitable candidate for the Best Researcher Award.

Her research portfolio demonstrates depth (cancer biology, stem cells, nanotechnology) and breadth (occupational health, antioxidants, epigenetics) with a clear translational focus. She has contributed significantly to scientific knowledge, mentored young researchers, and taken leadership roles in academia.

Sakthivel Muthu | Cancer biology | Best Researcher Award

Published on by Molecular Biologist

Dr. Sakthivel Muthu | Cancer biology | Best Researcher Award 

Assistant Professor, Saveetha Medical College and Hospital, Saveetha Institute of Medical and Technical Sciences (SIMATS), Thandalam, Chennai-602105, Tamil Nadu, India.

Dr. Sakthivel Muthu is a distinguished adjunct faculty at the Center for Global Health Research, Saveetha Medical College and Hospital, part of the Saveetha Institute of Medical and Technical Sciences (SIMATS), Chennai, India. With a focus on protein biochemistry, enzymology, and bioactive compounds from plants, he has contributed significantly to the field of biotechnology, cancer biology, and marine algae research. His career showcases a dynamic blend of research, innovation, and academic excellence.

Profile

Scopus

Google Scholar

ORCiD

Education

Dr. Muthu completed his Ph.D. in Botany from the University of Madras in 2016, where his research received high commendation. He earned his M.Phil. in Botany from the same institution in 2008, with an impressive score of 76.39%. Prior to that, he completed his M.Sc. in Botany from Madurai Kamaraj University in 2007 and his B.Sc. in Botany in 2005. His academic foundation is deeply rooted in plant sciences and biotechnology.

Experience

Dr. Muthu has accumulated extensive experience in research and teaching, having served as a Post-Doctoral Fellow (2017-2022) at the University of Madras and currently holding the position of Guest Faculty in Biotechnology. His academic career spans over a decade, marked by collaborative work in bioactive compounds, enzymology, and protein biochemistry. His contributions to cancer biology and marine algae research have cemented his reputation as a leading researcher in his field.

Research Interests

Dr. Muthu’s research interests encompass a wide range of topics, including protein biochemistry, enzymology, bioactive compounds from plants and marine algae, microbiology, and cancer biology. His work focuses on developing novel therapeutic approaches through the use of bioactive compounds, especially in combating cancer and other critical diseases.

Awards and Fellowships

Over the course of his academic journey, Dr. Muthu has received several prestigious awards. Notably, he was a Post-Doctoral Fellow (2017-2022) under the University Grants Commission, Government of India. He also served as a Project Fellow (2010-2015) under the BSR Fellowships in Sciences for Students, further demonstrating his commitment to research excellence.

Publications

Dr. Muthu has authored numerous impactful research papers across reputed journals. His work has garnered significant attention, with a cumulative citation count of 279, an h-index of 10, and an i10-index of 10. Some of his notable publications include:

  • Encapsulation of Phloroglucinol from Rosenvingea intricata Macroalgae with Zinc Oxide Nanoparticles against A549 Lung Cancer Cells
    • Published in Pharmaceutics (2024).
    • Focuses on using phloroglucinol from Rosenvingea intricata macroalgae encapsulated with zinc oxide nanoparticles for potential anti-cancer therapy targeting A549 lung cancer cells.
    • Cited by 4.
  • Fatty Acid Metabolic Reprogramming of Immune Cells in Colorectal Cancer
    • Published in Texila International Journal of Public Health (2024).
    • Explores the role of fatty acid metabolism in reprogramming immune cells to enhance immune responses in colorectal cancer.
    • Cited by 5.
  • Anthocyanin-rich Foods: Insights into Extraction, Medicinal Potential, and Sustainable Applications
    • Published in Journal of Agriculture and Food Research (2024).
    • Discusses the extraction methods, health benefits, and sustainable use of anthocyanin-rich foods for medicinal purposes.
    • Cited by 7.
  • Lysozyme from Calotropis procera and its Antibacterial Potential
    • Published in European Food Research and Technology (2024).
    • Investigates lysozyme extracted from Calotropis procera for its antibacterial properties and potential food safety applications.
    • Cited by 10.
  • Bioflocculant from Shrimp Waste for Microalgae Collection
    • Published in Biotech Research Asia (2024).
    • Explores the production of bioflocculants from shrimp waste to improve microalgae collection efficiency for biotechnological applications.
    • Citation count not specified.

Conclusion

Dr. Sakthivel Muthu is a strong contender for the Best Researcher Award based on his wide-ranging research expertise, significant publication record, and noteworthy citation metrics. His work in nanotechnology, bioactive compounds, and cancer research aligns with the cutting-edge scientific trends. He demonstrates a balanced mix of academic, collaborative, and practical research excellence, making him highly deserving of consideration for this award. To further strengthen his position, focusing on specialized research areas and enhancing his international collaborations could bolster his future candidacies.

 

Jiuda Zhao | Oncology – Breast Cancer | Best Researcher Award

Published on by Molecular Biologist

Prof. Jiuda Zhao | Oncology – Breast Cancer | Best Researcher Award

Chief Physician at Qinghai University Affiliated Hospital, China.

Jiuda Zhao is a Professor and Chief Physician at the Breast Disease Diagnosis and Treatment Center of the Affiliated Hospital of Qinghai University. With over 20 years of experience, he specializes in the diagnosis and treatment of breast cancer. He has been recognized as a high-end innovative talent and has contributed extensively to the field of oncology, focusing on advancing treatment methods for breast cancer.

Profile

Scopus

Education 

Jiuda Zhao completed his medical education and specialized training in oncology, focusing on breast cancer treatment. His academic journey is further complemented by his supervisory role, where he mentors doctoral students, contributing to the next generation of medical professionals in oncology.

Experience 

Jiuda Zhao has over two decades of clinical experience, particularly in the treatment of breast cancer. His work emphasizes diagnosis, innovative therapies such as immunotherapy and targeted treatments, and he is actively involved in multi-disciplinary approaches (MDT) for breast cancer care. He also contributes to the academic community by serving in various national oncology committees.

Research Interests 

Jiuda Zhao’s research is centered on the diagnosis and treatment of breast cancer, especially in high-altitude regions. His focus extends to endocrine therapy, targeted therapy, and immunotherapy, aiming to enhance treatment outcomes for patients. He is also involved in cross-disciplinary areas such as oncology cardiology and oncology genetics, promoting comprehensive cancer care.

Awards 

Jiuda Zhao has been honored multiple times for his contributions to oncology, including the prestigious Qinghai Provincial Science and Technology Progress Award in 2022. His commitment to cancer prevention and treatment has also earned him recognition as a high-level talent in Qinghai Province.

Publications 

1. Effect of Adding Electroacupuncture to Standard Triple Antiemetic Therapy on Chemotherapy-Induced Nausea and Vomiting: A Randomized Controlled Clinical Trial

  • Journal: Journal of Clinical Oncology
  • Published: September 6, 2024
  • DOI: 10.1200/JCO.24.00099
  • Authors: Shen G, Ren D, Zhao F, Wang M, Liu Z, Feng X, He Y, Liu X, Ling X, Zhao Y, Song F, Ma J, Li E, She T, Liu Z, Li Z, Huang S, Chen Y, Yang J, Li X, Duan L, Da M, Zheng Y, Li Y, Zhao J
  • Summary: This paper investigates the effectiveness of electroacupuncture in reducing chemotherapy-induced nausea and vomiting when added to the standard triple antiemetic therapy. The study is a randomized controlled trial, offering new insights into improving quality of life for chemotherapy patients.

2. Anlotinib: A Novel Multi-Targeting Tyrosine Kinase Inhibitor in Clinical Development

  • Journal: Journal of Hematology & Oncology
  • Published: September 19, 2018
  • DOI: 10.1186/s13045-018-0664-7
  • Authors: Shen G, Zheng F, Ren D, Du F, Dong Q, Wang Z, Zhao F, Ahmad R, Zhao J
  • Cited by: 462
  • Summary: This paper focuses on Anlotinib, a novel multi-targeting tyrosine kinase inhibitor used in cancer treatment. The research explores its efficacy in various cancer types, emphasizing its clinical potential as a therapeutic agent.

3. Incidence of Antibody-Drug Conjugates-Related Pneumonitis in Patients with Solid Tumors: A Systematic Review and Meta-Analysis

  • Journal: Critical Reviews in Oncology/Hematology
  • Published: April 2023
  • DOI: 10.1016/j.critrevonc.2023.103960
  • Authors: Zhu Z, Shen G, Li J, Qiu T, Fang Q, Zheng Y, Xin Y, Liu Z, Zhao F, Ren D, Zhao J
  • Summary: This meta-analysis assesses the incidence of pneumonitis caused by antibody-drug conjugates in solid tumor treatments. The study offers critical data for managing this rare but serious side effect in cancer therapy.

4. The Emerging Role of Hypoxia-Inducible Factor-2 Involved in Chemo/Radioresistance in Solid Tumors

  • Journal: Cancer Treatment Reviews
  • Published: July 2015
  • DOI: 10.1016/j.ctrv.2015.05.004
  • Authors: Zhao J, Du F, Luo Y, Shen G, Zheng F, Xu B
  • Summary: This paper discusses the role of Hypoxia-Inducible Factor-2 (HIF-2) in contributing to chemotherapy and radiotherapy resistance in solid tumors. It highlights new strategies for overcoming treatment resistance.

5. Association of Cyclin-Dependent Kinases 4 and 6 Inhibitors With Survival in Patients With Hormone Receptor-Positive Metastatic Breast Cancer: A Systematic Review and Meta-analysis

Conclusion

Jiuda Zhao is a highly deserving candidate for the Best Researcher Award. His significant contributions to breast cancer research, particularly in underserved high-altitude regions, demonstrate his expertise, leadership, and dedication to advancing medical science. His innovations, academic influence, and research outputs place him in a strong position for the award. Addressing areas like industry collaboration and international partnerships could further elevate his profile on a global scale.